fx-322

Small moleculeexperimental

Clinical trial activity

6 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started May 30, 2017 (NCT03300687)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05086276Phase 2Oct 12, 2021Frequency Therapeutics
NCT04629664Phase 1Nov 2, 2020Frequency Therapeutics
NCT04601909Phase 1Sep 17, 2020Frequency Therapeutics
NCT04120116Phase 2Oct 4, 2019Frequency Therapeutics
NCT03616223Phase 1/Phase 2 (Phase 2)Jul 3, 2018Frequency Therapeutics, Worldwide Clinical Trials
NCT03300687Early Phase 1 (Phase 1)May 30, 2017Frequency Therapeutics
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Frequency TherapeuticsFor profit6622017
Worldwide Clinical TrialsFor profit1012018
2 organizations
Page 1 / 1